Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] Hanmi Semiconductor (042700) – Preliminary Earnings Announcement (Fair Disclosure) / 2026-02-06 Semiconductors
  • [Disclosure] Hyundai Motor (005380) – Reference Price for Interim (Quarterly) Ex-Dividend (Hyundai Motor 2PB) / 2025-05-28 Disclosures
  • [Disclosure] Celltrion (068270) – Share Retirement Decision / 2024-04-17 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – (Correction) Resolution on Convening General Meeting of Shareholders / 2026-03-04 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Media Reports (Unconfirmed) / 2024-05-02 Disclosures
  • [Research] SK hynix (000660 / SKHY) – Mirae Asset | Memory Pricing · ADR Listing · Valuation Re-rating / 2026-03-23 RESEARCH
  • [Disclosure] ALTEOGEN (196170) – Additional Listing (Exercise of Stock Options) / 2026-05-13 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – (Correction) Loan Decision / 2025-06-30 Disclosures

[Disclosure] Hanwha Ocean (042660) – Change in Sales or Profit/Loss Structure by 30% (15% for Large Companies) or More / 2025-01-24

Posted on January 24, 2025August 8, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

Hanwha Ocean’s FY2024 consolidated revenue increased 45.5% year-over-year to KRW 10.78T, while operating profit turned to a profit of KRW 237.9B.

📊 [Key Disclosure Details & Financial Highlights]

  • Financial Statement Type: Consolidated Financial Statements (K-IFRS)
  • Changes in Revenue & Profit/Loss Structure:
    • Revenue: KRW 10,776,000,000,000 (approx. KRW 10.78T) / +45.5% (+KRW 3.37T) vs. KRW 7.41T in FY2023
    • Operating Profit: KRW 237,900,000,000 (approx. KRW 237.9B) / Turned to profit (+KRW 434.4B) vs. -KRW 196.5B in FY2023
    • Income Before Income Taxes: KRW 177,900,000,000 (approx. KRW 177.9B) / Turned to profit (+KRW 294.2B) vs. -KRW 116.3B in FY2023
    • Net Income: KRW 525,100,000,000 (approx. KRW 525.1B) / +228.2% (+KRW 365.1B) vs. KRW 160.0B in FY2023
  • Financial Position (Consolidated):
    • Total Assets: KRW 17.83T (FY2023: KRW 13.94T)
    • Total Liabilities: KRW 12.98T (FY2023: KRW 9.63T)
    • Total Equity: KRW 4.85T (FY2023: KRW 4.31T)
    • Capital Stock: KRW 1.54T (FY2023: KRW 1.54T)
    • Total Equity to Capital Stock Ratio: 315.6% (FY2023: 280.6%)
  • Primary Reasons for Changes:
    • Revenue growth and operating margin improvement driven by an increased proportion of LNGC revenue and general productivity enhancements
    • Increase in net income due to the recognition of deferred tax assets
  • Other Key Notes:
    • Figures are provisional results compiled prior to the completion of the external audit and are subject to potential adjustments during the audit process
    • The board resolution date (January 24, 2025) corresponds to the submission date of the pre-audit consolidated financial statements to the Securities and Futures Commission

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Verification of External Audit Results and Final Financial Statements

This disclosure presents preliminary performance results prepared before the completion of the external accounting audit. Checking whether any differences exist between these preliminary figures and the final confirmed numbers upon completion of the external audit is essential for determining the finalized accuracy of the financial metrics. The final numbers can be verified under the ‘Submission of Audit Report’ disclosure and the financial statements section of the upcoming Annual Report.

📢 Disclaimer & Fact Source

Source: This content was structured and newly written based on officially submitted data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Disclaimer: This material is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Shipbuilding

Post navigation

Previous Post: [Disclosure] Hanwha Ocean (042660) – Provisional Consolidated Financial Results (Fair Disclosure) / 2025-01-24
Next Post: [Disclosure] Hanwha Aerospace (012450) – Clarification of Rumors or Reports (Unconfirmed) / 2025-01-24

Related Posts

  • [Disclosure] Hanwha Aerospace (012450) – Investor Relations (IR) Announcement / 2024-10-15 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – Pre-announcement of Earnings Release / 2026-01-20 Disclosures
  • [Disclosure] ISU PETASYS (007660) – Investor Relations (IR) Announcement / 2024-02-28 Semiconductors
  • [Disclosure] Hanwha Aerospace (012450) – Investor Relations (IR) Presentation / 2026-02-26 Disclosures
  • [Disclosure] Samsung Electronics (005930) – Results of Annual General Meeting of Shareholders / 2026-03-18 Semiconductors
  • [Disclosure] Daeduck Electronics (353200) – Provisional Operating Results (Consolidated Financial Basis) / 2026-07-31 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Advance Notice of Earnings Release / 2024-10-15 Disclosures
  • [Disclosure] Hanwha Ocean (042660) – Investor Relations (IR) Presentation / 2025-04-14 Disclosures
  • [Research] Samsung Electro-Mechanics (009150) – Yuanta Securities | Server Demand · MLCC Pricing · Dual Upcycle / 2026-03-12 RESEARCH
  • [Disclosure] Celltrion (068270) – Application for Phase 3 Clinical Trial Plan for CT-P55 (Cosentyx Biosimilar) in the U.S. / 2024-07-01 Disclosures
  • [Disclosure] SK Square (402340) – Decision on Record Date for Cash/In-Kind Dividend / 2025-10-29 Semiconductors
  • [Disclosure] Hyundai Motor (005380) – Status of Compliance Program Operation (Notice) / 2024-10-24 Disclosures
  • [Disclosure] Celltrion (068270) – Approval of Korean MFDS Marketing Authorization for Avtozma Subcutaneous Injection (CT-P47, Actemra Biosimilar) / 2025-02-13 Disclosures
  • [Disclosure] HPSP (403870) – Results of Annual General Meeting of Shareholders / 2024-03-29 Semiconductors

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme